Omidenepag Isopropyl

Summary

Omidenepag Isopropyl (CHEMBL4297666) is an approved small molecule; indicated across 3 conditions including open-angle glaucoma and ocular hypertension.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 520.6 Da · C26H28N6O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297666
Name	Omidenepag Isopropyl
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	44230999
Molecular formula	C26H28N6O4S
Molecular weight	520.6
InChIKey	VIQCWEGEHRBLAC-UHFFFAOYSA-N

SMILES: CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4

IUPAC name: propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]-2-pyridinyl]amino]acetate

Also known as: De-117, DE-117, Omidenepag isopropyl, Omlonti, OMIDENEPAG ISOPROPYL, Omnidenepag Isopropyl

Patent coverage: 36 distinct patent families (107 SureChEMBL compound mentions), from 3 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin E2 receptor EP2 subtype.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGER2	8.96	EC50	1.1	nM	CHEMBL_ACT_26123577
PTGER2	5.38	IC50	4180	nM	CHEMBL_ACT_18932306

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
open-angle glaucoma	4	MONDO:0005338	EFO:0004190
ocular hypertension	4	MONDO:0006875	EFO:1001069
glaucoma	3	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02981446	PHASE3	COMPLETED	A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
NCT01654484	PHASE1/PHASE2	COMPLETED	A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
NCT02650063	PHASE1	COMPLETED	A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).